Pexelizumab fails to inhibit assembly of the terminal complement complex in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Insight from a substudy of the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial.
暂无分享,去创建一个
P. Armstrong | C. Granger | A. Stebbins | A. Fortier | A. Bonnefoy | C. Martel | M. Ghitescu | P. Théroux